AU2022291585B2 — Methods of using a GIP/GLP1 co-agonist for therapy
Assigned to Eli Lilly and Co · Expires 2024-08-15 · 2y expired
What this patent protects
METHODS OF USING A GIP/GLP1 CO-AGONIST FOR THERAPY ABSTRACT 5 The present invention provides a method for increasing glycemic control in a patient in need thereof, by administering tirzepatide, or a pharmaceutically acceptable salt thereof. The present invention provides a me…
USPTO Abstract
METHODS OF USING A GIP/GLP1 CO-AGONIST FOR THERAPY ABSTRACT 5 The present invention provides a method for increasing glycemic control in a patient in need thereof, by administering tirzepatide, or a pharmaceutically acceptable salt thereof. The present invention provides a method for improving weight management in a patient in need thereof, by administering tirzepatide, or a pharmaceutically acceptable salt thereof. Further providing a method for treating a condition selected from 10 atherosclerosis, chronic kidney disease, NAFLD, and NASH. Further provided is a method to prevent or induce remission of diabetes comprising administration of tirzepatide, or a pharmaceutically acceptable salt thereof. Further provided is a dosing regimen for increasing glycemic control, improving weight management, and/or treating dyslipidemia. 15
Drugs covered by this patent
- Mounjaro (TIRZEPATIDE) · Eli Lilly
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.